CD8A and neoplasm: As ccRCC enters the immunotherapy era, elevation in tumor-infiltrating CD8+ T cells, though they have been known as a bad prognosis before immunotherapy became the standard frontline treatment, provides an immune-hot microenvironment for ICI to work.